Lumicell Announces U.S. Launch and First Commercial Use of LumiSystem™, Pioneering Real-Time Detection of Residual Breast Cancer During Lumpectomy
LumiSystem is the first and only fluorescence-guided imaging technology for breast cancer detection, enabling a more complete resection Newton, MA – Lumicell, Inc., a leader in developing innovative fluorescence-guided imaging technologies for cancer detection, today announced the U.S. commercial availability and first commercial use of LumiSystem™. This groundbreaking system combines two recently FDA-approved products: LUMISIGHT™, […]
Lumicell Announces Accomplished Healthcare Leader as New Member to Board of Directors
Independent director, Jim Alecxih, Chief Executive Officer of DH Medical joins Lumicell’s Board of Directors NEWTON, Mass., Jan. 6, 2025 – Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is pleased to announce the appointment of Jim Alecxih to its Board of Directors. The Lumicell […]
Lumicell Announces Poster Presentations at the 2024 San Antonio Breast Cancer Symposium Focused on Patient Benefit of Using LumiSystem™ During Lumpectomy
New data suggests that patients were satisfied with their cosmetic outcomes following the removal of suspicious tissue detected by fluorescence-guided imaging during lumpectomy surgery, and prefer to avoid a second surgery Adding LumiSystem to a lumpectomy procedure may lead to a reduction in targeted volume of radiation therapy for some patients and may lead to […]
Lumicell Granted Permanent HCPCS Code for Intraoperative Fluorescence Imaging Margin Assessment
Permanent HCPCS code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ Direct Visualization System (DVS), together referred to as LumiSystem™, with commercial availability in Q4 2024 NEWTON, Mass.—Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today announced LUMISIGHT™ (pegulicianine) was granted […]
Lumicell’s Board of Directors Appoints Howard Hechler as Chief Executive Officer
NEWTON, Mass., Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is proud to announce the appointment of Howard Hechler as Chief Executive Officer. “The Board of Directors is highly confident in Howard’s ability to inspire robust investment into this unparalleled opportunity” said Andrey Zarur, […]
Lumicell’s LumiSystem™ Featured on Viewpoint with Dennis Quaid for New Episode on Fluorescence-Imaging Guidance During Lumpectomy Surgery
NEWTON, Mass., —Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, is thrilled to announce its upcoming collaboration for an episode of “Viewpoint,” the acclaimed educational program hosted by Dennis Quaid. The segment exploring advancements in fluorescence-imaging technology in surgery for breast cancer will delve […]
Lumicell Awarded Phase I NIH SBIR Contract to Develop Novel Flexible Endoscope for Fluorescence Imaging of LUMISIGHT™ to Detect Early Esophageal Lesions in Patients with Barrett’s Esophagus
Funding of approximately $400,000 will support development of novel endoscopic imaging platform combining far-red fluorescence and reflected light imaging to detect esophageal cancer NEWTON, Mass.,—Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today announced Lumicell was awarded a Phase I Small Business Innovation Research […]
CMS Grants Transitional Pass-Through Payment for LUMISIGHT™ (pegulicianine) and Increases Access for Patients with Breast Cancer
Transitional pass-through payment of optical imaging agent LUMISIGHT is effective October 1, 2024, as part of the hospital outpatient prospective payment system (OPPS) NEWTON, Mass.,—Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today announced that the Centers for Medicare & Medicaid Services (CMS) has […]
Lumicell Announces New Category III CPT® Code for Intraoperative Fluorescence Imaging Margin Assessment in Support of Market Launch
Add-on CPT code granted following U.S. FDA approval of LUMISIGHT™ (pegulicianine) and Lumicell™ DVS, together referred to as LumiSystem™, with commercial availability in Q4 2024 NEWTON, Mass., July 15, 2024—Lumicell, Inc., a privately held company focused on developing innovative fluorescence-guided imaging technologies for cancerous tissue detection during surgery, today announced the American Medical Association has […]
Lumicell’s Cutting-Edge Imaging Platform Receives Historic FDA Approval to Illuminate Residual Breast Cancer
LUMISIGHT™ and Lumicell™ Direct Visualization System (DVS) offer 84% diagnostic accuracy in detecting residual cancer, in real-time, that may have been otherwise missed during lumpectomy surgery, while sparing some from second surgeries LUMISIGHT and Lumicell DVS previously received FDA Fast Track and Breakthrough Device designations, respectively NEWTON, Mass., April 18, 2024—Lumicell, Inc., a […]
